Mometasone Furoate

Mometasone furoate is a synthetic glucocorticoid, one of the corticosteroid family of anti-inflammatory drugs. Chemically it is a furoate ester of the steroid mometasone, and it binds with high affinity to the glucocorticoid receptor, which is the basis of its potent suppression of inflammation ^[1][3].

The drug was patented in 1981 and came into medical use in 1987. It is regarded as a well-established treatment, features on the World Health Organization's Model List of Essential Medicines, and is now available in generic form ^[3]. A notable feature is that very little of the drug is absorbed into the bloodstream when applied to the skin, the nose or the airways, which helps confine its effects to the site of application and contributes to its favorable tolerability ^[2].

Mometasone furoate is used across three main routes. Applied to the skin as a cream or ointment, it treats inflammatory skin disorders such as eczema and psoriasis. Delivered as a nasal spray, it is a first-line option for seasonal and perennial allergic rhinitis (hay fever) and for nasal polyps, and reviews have judged the evidence for its efficacy in allergic rhinitis to be strong ^[1][2]. Given by inhaler, it is used for the maintenance treatment of asthma, where it improves lung function and symptom control and has performed comparably to other inhaled corticosteroids such as budesonide, beclomethasone and fluticasone; it is meant for ongoing prevention rather than for relieving an acute attack ^[3].

The medicine is supplied as topical creams and ointments, metered nasal sprays and oral inhalers. Its regulatory status varies by country and formulation: the nasal spray is available over the counter in the United States, while other forms and jurisdictions generally require a prescription ^[2][3].

This is a prescription topical steroid. Common local effects include burning, stinging, dryness, and with long or heavy use, thinning of the skin, stretch marks, visible small blood vessels, and acne-like eruptions. Applying it to large areas, under airtight dressings, or on thin skin like the face and groin raises absorption and the odds of side effects. It should not go on untreated skin infections, and prolonged use in children carries a higher risk of suppressing the cortisol axis because they absorb more relative to body size. Keep it away from the eyes.

Mometasone furoate has one interaction carrying real risk, and it is metabolic. Mometasone is a CYP3A4 substrate whose safety at intranasal and inhaled doses rests on near-complete first-pass clearance; systemic bioavailability is under 1%. Strong CYP3A4 inhibition removes that protection.

Ritonavir and cobicistat are the inhibitors that have caused harm in practice. The published cases of iatrogenic Cushing's syndrome and adrenal suppression from intranasal or inhaled corticosteroids taken with boosted antiretrovirals involve fluticasone and budesonide most often, and a systematic review of those reports flagged mometasone as sharing enough pharmacokinetic character with fluticasone to warrant the same caution. Itraconazole, ketoconazole and clarithromycin act through the same enzyme.

Topical mometasone on intact skin has essentially no interaction profile. The standard corticosteroid cautions about live vaccines and blood glucose apply only at exposures high enough to become systemic.

Checking a whole stack? Run it through interactions + stacks.

Mometasone furoate is a synthetic corticosteroid developed by Schering-Plough; it was patented in 1981 and introduced for clinical use in the late 1980s. It was engineered as a potent topical glucocorticoid whose furoate ester enhances receptor binding and skin penetration while keeping systemic absorption low. First marketed as a topical cream and ointment (Elocon) for inflammatory skin conditions, it was later formulated as an aqueous nasal spray (Nasonex) for allergic rhinitis and nasal polyps, and subsequently as a dry-powder inhaler for asthma maintenance. Its broad utility across skin, nose, and airway, combined with a favorable local-versus-systemic profile, earned it a place on the World Health Organization's List of Essential Medicines. It is now widely available as a generic in multiple formulations.

Mometasone furoate is regarded as a workhorse corticosteroid with an excellent balance of potency and safety, which is precisely why it appears in so many different products and on essential-medicines lists. In the nose it is a trusted first-line treatment for hay fever and nasal polyps; on the skin it is a dependable mid-to-high potency option for eczema and psoriasis; and in inhaled form it helps keep asthma under control. Its key virtue is that very little of a topical, nasal, or inhaled dose reaches the bloodstream, so it delivers strong local anti-inflammatory action with a low burden of systemic steroid effects. Clinicians and patients value its once-daily dosing and long safety record. As with any corticosteroid, prolonged or heavy use warrants care, but within its intended uses it is considered both effective and reassuringly well tolerated.